The discovery of therapeutic miRNAs is one of the most exciting challenges for
pharmaceutical companies. Since the first miRNA was discovered in 1993, our knowledge of …

Prostate cancer (PCa) is the second most prevalent cancer in men worldwide, presenting a
significant global public health challenge that necessitates early detection and personalized …

Current approaches for prostate cancer (PCa) diagnosis and risk stratification require
greater accuracy. Extracellular vesicles and particles (EVPs) containing diverse cargos from …

Extracellular vesicles and nanoparticles (EVPs) are now recognized as a novel form of cell–
cell communication. All cells release a wide array of heterogeneous EVPs with distinct …

Prostate cancer, a leading cause of cancer-related mortality among men, often presents
challenges in accurate diagnosis and effective monitoring. This systematic review explores …

Prostate cancer is among the most common cancers in males. Recent application of system
biology methods has resulted in identification of key genes in the process of carcinogenesis …

Background Anlotinib is a targeted therapy indicated for some malignancies, including
advanced non-small cell lung cancer (NSCLC). However, noninvasive biomarkers for …

Extracellular vesicles (EVs) have emerged as key players in intercellular communication,
disease pathology, and therapeutic innovation. Initially overlooked as cellular debris, EVs …

前列腺癌(PCa) 起病隐匿, 大多数患者确诊时即处于疾病晚期且预后不良. 外泌体是细胞释放到
体液中的细胞外囊泡, 肿瘤细胞来源的外泌体含有肿瘤的遗传信息, 包括DNA, RNA, 蛋白质等 …

Background. The tumor microenvironment (TME) plays an important role in the occurrence
and progression of prostate cancer (PCa). At the same time, the mechanisms and features of …